A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
Condition: Primary Central Nervous System Lymphoma Interventions: Drug: Orelabrutinib; Drug: Rituximab; Drug: Methotrexate (MTX); Drug: Dexamethasone Sponsor: Huashan Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials